Plenty of orders on hand
The company said that, affected by the new Crown pneumonia epidemic, the implementation of overseas projects with high gross profit margins was blocked, and the domestic project delayed the recognition of increased costs, resulting in the company's overall gross profit decline. As the automotive industry rebounded during the reporting period, downstream customers' willingness to increase capital expenditures, the gross profit margin of new orders signed during the reporting period gradually returned to the normal range, the impact on profit due to the decline in gross profit margin will be gradually eliminated.
With the easing of the domestic epidemic, the company's domestic business has basically returned to normal since the second quarter, with plenty of orders in hand. The company is actively expanding the customers of high-end automobile enterprises. During the reporting period, the company has established cooperative relationships with BMW, Mercedes-Benz and Tesla (Shanghai). At the same time, the company is actively expanding the new energy automobile customers, at present, the company's orders on hand in the new energy automobile orders accounted for about 30%.
In the first half of the year, in order to stabilize the company's automated welding of automotive body-in-white industry leading position and the sustainable development of business, the company actively adjusted the customer structure of the high-end intelligent equipment manufacturing industry and the direction of business development, during the reporting period, Tianjin Fuzhen actively promote the establishment of a subsidiary in Germany, and actively "go out" to expand overseas market business for the future business, at present, the company has established cooperation with BMW, Mercedes-Benz (Shanghai). During the reporting period, Tianjin Fuzhen actively promoted the establishment of a German subsidiary to actively "go out" and expand overseas market business for the future business. At present, Fuzhen and Ruifu are following up on overseas projects, such as the automation production line projects of Tesla USA, Magna, Ford, BMW and other OEMs and automotive parts suppliers.
In the first half of the year, HGI saw a significant year-on-year decline in all three expenses. This is mainly attributed to the company's refined management objectives, improve overall operational efficiency, and continue to promote cost reduction and efficiency.
R & D expenses increased by nearly 30% year-on-year
The announcement shows that in the first half of the year, HGI adhered to the core of technological innovation, independent research and development as a guide, and continued to encode the innovation and research and development, R & D investment of 34,684,500 yuan, an increase of 28.14% year-on-year, accounting for as high as 4.5% of the proportion of revenue. In the first half of the year, the company *** new invention patents 4, utility model patents 47, appearance patents 1, new software copyright 16; as of June 30, the company *** have authorized patents 190, of which 15 invention patents, software copyright 99.
In addition to the high-end intelligent equipment manufacturing business on the adjustment, the company will focus more on the product category business market development. During the reporting period, the company signed a robot body sales of more than 500 units, will be completed according to customer demand for delivery, and Fei Koteng Intelligent Technology (Qingdao) Co., Ltd. and IZP Precision Machinery (Suzhou) Co. More than 1,000 sets of robot body in the follow-up, including several automotive OEMs, this year is expected to realize the breakthrough of domestic robot body in the automotive industry applications.
In 2019, the company's industrial intelligent design software (AIAD V1.0) launched at the Industrial Fair also completed further iteration during the reporting period, completed the packaging of the industrial intelligent design software (AIAD V1.2) and put into the verification of the use of the actual automotive welding line fixture design work.
In addition to the application of "AI+ROBOT" in the industrial field, the Company has also actively explored the application of "AI+ROBOT" in the field of medical devices, and in the second half of 2018, the Company's Central Research Institute initiated the blood collection robot's In the second half of 2018, the company's Central Research Institute initiated the design and development of blood collection robots. The blood collection robot is an under-image assisted puncture product, which belongs to Class III (interventional) of medical devices, and it collects blood through a vein, which is mainly used for blood tests such as routine blood tests and biochemical tests. During the reporting period, the Central Research Institute successfully completed the design and development of the fully automated blood collection robot and desktop blood collection robot prototype by utilizing medical image processing, micro-control technology, multi-modal sensing technology and AI algorithm. The company said that a series of medical robot product lines such as anesthesia analgesia robot and tumor ablation robot will be derived from this platform in the future, which will be applied in different clinical scenarios.